Mkt view :
Only 290 companies trading above dec 2017 prices which was top of overall broader market. If one looks at nifty which is concentrated in 5 stocks, then it may scare them. Whereas individual stocks have yet lot of room to grow.
In history of markets, when interest rates can not grow and remain so low for another 1 year minimum then stock prices are bound to soar.
How to play in current markets : 1. Debt free and low working capital companies ( as% of sales) with less receivable days and small cash conversion cycles . This ensures company always has money to operate n stay afloat.
2. High growth companies with above 1st condition. Top line of 10% plus and bottom line of 25% plus consistently with increasing or stable operating margins make the company do better in robustness of share price.
In such pandemic corona conditions or earlier demonetization, nbfc liquidity crunch, ilfs, small & midcap dwnfall from 2018: if all of these situations can not stop these companies then What will?
They remained robust and grew in profits and share prices. That's what we are choosing. If there is correction in stock price, it will never set a panic or regret, one would be willing to add n load it up. Only those are the companies worth buying.
Companies should have individual strong growth levers and also they should be trying to be global players with product and process evolvement like high value adding product launches, cutting dwn costs, entering new teritories, signing multiyear mega contracts -
with size of opportunity / available market to sell expanding for them. Where peer companies of theirs locally or globally are not able to compete with them in terms of margins, quality or scale
We have chosen Such 10-12 Companies where management is clear and working hard and smart on plans. "What is going to happen to their profits" Has very much clarity. Then question remains what investor is going to do about it?
to know more contact us at invest@wealthyvia.com , 8369508540
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Price brand 423-425 , lot size 35. Fresh issue will get 50 cr rest OFS of 446 cr
Listing date: Based on the indicative timeline, trading is likely to commence on July 23.
Pre-IPO placements: Rossari Biotech on Friday said it has raised Rs 149 crore from anchor investors. like ADIA, HDFC MF, Axis MF, ICICI Pru MF, SBI MF, Goldman Sachs India etc.
Promoter background: VJTI and UDCT Engineering, MBA Welingkar. Self-made first gen. Expert in Chemicals. After the share sale, the total promoter shareholding will fall to 73% from 95%.
Stock has already given 23% returns since recommendation.
Contact us at invest@wealthyvia.com or +91 83695 08540 for more details & research reports.
1/n
India is one of the biggest markets for gold and gold loan. According to World Gold Council, India accounts for 10% of total world gold stock and is world’s largest gold consumer, India accounted for 23% gold loan demand globally.
2/n
India's gold loan market is expected to reach Rs 4,617 billion by 2022 at a 5Y compounded annual growth rate of 13.4%.
Approx 35% of the gold loan market with commercial banks, NBFCs and small finance banks being the key players. The unorganized segment is twice as large.
3/n
Should be on Top 3 players in its respective market.
If not, is the company capturing market share from the incumbents with the launch of unique or niche products, entering new markets, new brands, patents etc ?
Alembic Pharma is up 50% since we recommended the stocks to our retail & institutional clients. And here is a thread on why we are still bullish on it with a Target Price of 2100.
Alembic Pharma was only in OSD (Oral solid dosages) earlier & the company had strategically moved up the value chain towards Formulations. In the last 4 years the company has transformed from 2 formulations to 6 currently.
2/n
The company is fast growing its presence in verticals like Injectables , Oncology, Dermatology, Ophthalmology. Highest R&D spend as % of sales (15%) when compared to the median of 8% across other pharma majors.
3/n
MSME - Facts, Reforms & Current Situation - A Thread
According to government numbers, there were about 65 million plus MSME units accounting for about 28% of the GDP and 30% of India’s labour force.
As report by TransUnion CIBIL- SIDBI of April, the total on-balance sheet commercial lending exposure in India stood at ₹64.45 lakh crores as of January 2020 compared to ₹64.04 lakh crores in December 2019. MSME Segment is at ₹17.75 lakh crore credit exposure as of Jan2020.